Depression: all studies (page 441) - The Consciousness Library

828. Psilocin attenuates polyinosinic:polycytidylic acid (Poly I:C)-indued interferon responses in human peripheral blood mononuclear cells

The International Journal of Neuropsychopharmacology September 1, 2026 Christopher Sheridan, Guillaume Thuery, K Brennan et al.

Abstract Background Serotonergic psychedelics have recently re-emerged as promising therapeutic agents in psychiatry, showing positive outcomes in clinical trials for treatment-resistant depression, major depression, and PTSD. However, their effects on the immune system are poorly characterized. It remains unclear whether these compounds exert immunomodulatory effects that contribute to their...

DOI: 10.1093/ijnp/pyag040.414 Full text

Psilocybin Restores Spatial Memory but Not Fronto-Hippocampal Synchrony in a Rat Model of Alzheimer's Disease

Neuroscience Research September 1, 2026 Mersedeh Shamsedin

ABSTRACT Background Fronto-hippocampal desynchronization is linked to cognitive decline in Alzheimer's-like pathology, but whether psilocybin can restore this dysfunction is unknown. Methods Male rats received intracerebroventricular streptozotocin (ICV-STZ) to induce neurotoxicity, followed by a single dose of psilocybin (2.5 mg/kg, the maximum tolerated dose). Spatial memory, recognition...

DOI: 10.1016/j.neures.2026.105117

Psilocybin, From Ancestral Use to Therapeutic Potential: A Multidimensional Review of Its Pharmacological Basis and Current Perspectives

Human Psychopharmacology: Clinical and Experimental September 1, 2026 José Norberto Vásquez-Bonilla

OBJECTIVE: This review critically examines psilocybin, with particular emphasis on its pharmacokinetics and pharmacodynamics, including its serotonergic, neuroplastic, and anti-inflammatory mechanisms. It integrates historical context, preclinical and clinical evidence, and evaluates emerging therapeutic potential, safety, microdosing practices, and pharmacological interactions. METHODS: A...

DOI: 10.1002/hup.70063

The mPFC-reuniens-hippocampus pathway links brain circuitry and neural plasticity in antidepressant response

Nature Communications September 1, 2026 Maxime Veleanu, Louise E. Schuberth, Antje Kilias et al.

The pathophysiology of depression involves multiple biological processes, including circuit dysfunction and impaired neuroplasticity, yet an integrative view linking these processes remains elusive. Here, we identify a convergent circuit for antidepressant response and plasticity modulation. We demonstrate that chemogenetic activation of the infralimbic cortex (IL) exerts rapid...

DOI: 10.1038/s41467-026-77248-y Full text

Factors Associated with Intentions to Use Psilocybin for Mental Health in Relation to Psychotherapy, Psychiatric Medications, and Natural/Synthetic Options

Journal of Psychoactive Drugs September 1, 2026 Brian P. Meier, Courtney M. Lappas, Matthew W. Johnson

= 1,102), we examined the intentions to use psilocybin in a mental health context in relation to psychotherapy, psychiatric medication, and natural versus synthetic options. We also examined potential predictors of the intentions to use psilocybin. In Study 1, we found that participants had significantly lower intentions to use psilocybin in a mental health context versus psychotherapy and...

DOI: 10.1080/02791072.2026.2727013

Buprenorphine following ketamine treatment enhances anti‐suicidal effects

The Brown University Psychopharmacology Update September 1, 2026

Patients with major depressive disorder (MDD) who received 4 weeks of buprenorphine treatment following a single infusion of ketamine experienced a significant reduction in suicidal ideation compared with ketamine plus placebo, a randomized, double‐blind trial has found. No serious treatment‐related adverse events were reported. Study results were published online May 19, 2026 in the American...

DOI: 10.1002/pu.31484

Psilocibina e neuroplasticidade: novas perspectivas terapêuticas para depressão resistente

Vértices September 1, 2026 Leticia Almeida Castro, André Luiz Anjos Simões Júnior, Guilherme Gianizeli Corradi Simões et al.

Depression is a multifactorial mental disorder and a leading cause of global disability. A subset of patients does not respond to conventional antidepressants, characterizing treatment-resistant depression (TRD). This study aimed to investigate the therapeutic potential of psilocybin in TRD, focusing on its effects on neuroplasticity. An integrative literature review was conducted using PubMed,...

DOI: 10.19180/1809-2667.v28n22026.23658

Beyond Efficacy Signals: Regulatory, Methodological, and Translational Challenges in Clinical Research on Ketamine and Psilocybin in Psychiatry

Psychiatry International September 1, 2026 Damian Swieczkowski, Michal Pruc, Lukasz Szarpak et al.

Major depressive disorder (MDD) and treatment-resistant depression (TRD) continue to drive interest in ketamine-family compounds and psilocybin, but antidepressant efficacy alone does not establish whether these interventions can be evaluated reliably or implemented responsibly. We conducted a structured narrative review using targeted PubMed/MEDLINE searches through 21 July 2026,...

DOI: 10.3390/psychiatryint7050190

Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress.

Neuropsychopharmacology Reports September 1, 2026 Daisuke Ibi, Rika Takaba, Keisuke Yoshida et al.

Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) exert hallucinogenic effects through stimulation of serotonin 5-HT2A receptors (5-HT2ARs) in the cerebral cortex. In recent years, numerous reports have demonstrated that psychedelics are effective in treating various psychiatric disorders such as major depressive disorder (MDD), treatment-resistant depression (TRD), and...

DOI: 10.1002/npr2.70152 Psilocybin Psilocin Animals Mice, inbred c57bl +8

Mindfulness in the Brazilian National Health System (SUS): Why Training Instructors Is Not Expensive but Strategic and Cost-Effective

Qeios August 31, 2026 Marcelo Demarzo

BACKGROUND: It is often argued that training mindfulness instructors would be too expensive to be feasible within a public health system such as Brazil’s Unified Health System (SUS). This essay challenges that perception by combining epidemiological estimates, cost analysis, and evidence from national and international experiences. METHODS: Using population-based planning benchmarks, we...

DOI: 10.32388/7ng75x.2